152 related articles for article (PubMed ID: 30151560)
21. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
Hackert T; Ulrich A; Büchler MW
Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
[No Abstract] [Full Text] [Related]
22. Role of surgery in pancreatic cancer.
Buanes TA
World J Gastroenterol; 2017 Jun; 23(21):3765-3770. PubMed ID: 28638216
[TBL] [Abstract][Full Text] [Related]
23. Treatment and Survival of Elderly Patients with Stage I-II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium.
Groen JV; Douwes TA; van Eycken E; van der Geest LGM; Johannesen TB; Besselink MG; Koerkamp BG; Wilmink JW; Bonsing BA; Portielje JEA; van de Velde CJH; Bastiaannet E; Mieog JSD;
Ann Surg Oncol; 2020 Dec; 27(13):5337-5346. PubMed ID: 32388741
[TBL] [Abstract][Full Text] [Related]
24. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
[TBL] [Abstract][Full Text] [Related]
26. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma.
Duconseil P; Garnier J; Weets V; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Poizat F; Giovannini M; Delpero JR; Turrini O
World J Surg Oncol; 2019 Jun; 17(1):95. PubMed ID: 31164144
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
[TBL] [Abstract][Full Text] [Related]
28. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant
Hashmi A; Kozick Z; Fluck M; Hunsinger MA; Wild J; Arora TK; Shabahang MM; Blansfield JA
Am Surg; 2018 Sep; 84(9):1439-1445. PubMed ID: 30268172
[TBL] [Abstract][Full Text] [Related]
30. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
Mirkin KA; Hollenbeak CS; Wong J
Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant therapy for resectable pancreatic cancer.
Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
[TBL] [Abstract][Full Text] [Related]
32. Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer.
Bergquist JR; Ivanics T; Shubert CR; Habermann EB; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB; Truty MJ
Ann Surg Oncol; 2017 Jun; 24(6):1731-1738. PubMed ID: 28070725
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.
Sener SF; Fremgen A; Menck HR; Winchester DP
J Am Coll Surg; 1999 Jul; 189(1):1-7. PubMed ID: 10401733
[TBL] [Abstract][Full Text] [Related]
34. Postoperative mortality following multi-modality therapy for pancreatic cancer: Analysis of the SEER-Medicare data.
Nayar P; Chandak A; Gupta N; Yu F; Qiu F; Ganti AK; Are C
J Surg Oncol; 2017 Feb; 115(2):158-163. PubMed ID: 28133817
[TBL] [Abstract][Full Text] [Related]
35. Sequential and/or concurrent hypofractionated radiotherapy and concurrent chemotherapy in neoadjuvant treatment of advanced adenocarcinoma of the pancreas. Outcome and patterns of failure.
Zimmermann FB; Schuhmacher C; Lersch C; Bernhardt B; Pickel P; Siewert JR; Molls M; Jeremic B
Hepatogastroenterology; 2004; 51(60):1842-6. PubMed ID: 15532839
[TBL] [Abstract][Full Text] [Related]
36. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
[TBL] [Abstract][Full Text] [Related]
37. Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma.
Swords DS; Firpo MA; Johnson KM; Boucher KM; Scaife CL; Mulvihill SJ
Surgery; 2017 Jul; 162(1):104-111. PubMed ID: 28238344
[TBL] [Abstract][Full Text] [Related]
38. Case Report: Long-Term Survival in Patients with Initial Lung-Only Metastasis from Pancreatic Adenocarcinoma.
Gotfried JI; Kozuch PS
J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S50-5. PubMed ID: 21755284
[No Abstract] [Full Text] [Related]
39. [Neoadjuvant and adjuvant therapy of ductal pancreatic carcinoma].
Hohenberger W; Kastl S
Zentralbl Chir; 2000; 125(4):348-55. PubMed ID: 10829315
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
